We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Mass Spectrometry Detects Bacteria Without Time-Consuming Isolation and Multiplication

By LabMedica International staff writers
Posted on 06 May 2025

Speed and accuracy are essential when diagnosing diseases. More...

Traditionally, diagnosing bacterial infections involves the labor-intensive process of isolating pathogens and cultivating bacterial cultures, often resulting in several days of waiting before targeted treatment can begin. Researchers have now developed a groundbreaking method that can identify bacteria with unprecedented speed, reducing the waiting time from several days to just a few minutes.

The innovative approach, developed by researchers at Technical University of Munich (TUM, Munich, Germany) and Imperial College London (London, UK) uses mass spectrometry to detect specific metabolic products of bacteria directly from tissue and stool samples. Central to this process is a database that currently includes 232 medically relevant bacterial species and their associated metabolic products. From this database, biomarkers are extracted to allow for the direct identification of specific bacteria.

The new method is capable of identifying bacteria responsible for a variety of serious conditions, including stomach cancer, pneumonia, meningitis, preterm birth, gonorrhea, and sepsis. To ensure that this method becomes a regular tool in clinical settings, the biomarker database needs to be expanded. The researchers note that over 1,400 bacterial pathogens are known, and their specific metabolic products need to be identified and added to the database. The team also sees significant potential for this method in personalized medicine, where treatments can be tailored precisely to individual patients based on the specific bacteria detected.

"Our innovative approach is not to look directly for the pathogenic bacteria, but only for their metabolic products. This allows us to detect them indirectly, but much more quickly," said first author Wei Chen.

"This is one of the most important future topics in biotechnology and medicine. Targeted interventions can dramatically improve the chances of successful treatment. As analysts, we develop modern tools and methods for doctors to do this," added Prof. Nicole Strittmatter.

Related Links:
TUM 
Imperial College London 


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
LAIR2 Antibody Pair Set
LAIR2 Antibody Pair [Biotin]
Platinum Member
Integrated Biochemical & Immunological System
Biolumi CX Solution X10+C10
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Pathology

view channel
Image: A new study demonstrates that vascular features in colorectal tumors could serve as prognostic biomarkers of disease outcome. (Image Credit: iStock)

Tumor Blood Vessel Features May Help Predict Colorectal Cancer Survival

Colorectal cancer outcomes vary widely, and tumor biology remains a key determinant of prognosis. Because neoplasms depend on a vascular supply, differences in intratumoral vessels may influence survival.... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image Credit: Adobe Stock

Mayo Clinic and Thermo Fisher Launch Multi-Omics Venture to Identify Early Disease Signals

Many diseases begin developing years before symptoms emerge, making early detection difficult for healthcare systems and clinical laboratories. Linking molecular changes with longitudinal health data could... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.